News about Industrial talks

Pfizer Chief Criticises FDA Vaccine Unit Leadership and Decision-Making

Pfizer Chief Executive Officer Albert Bourla has publicly raised concerns about the leadership of the US Food and Drug Administration’s vaccine and biologics division, citing internal discord and recent regulatory decisions as problematic.

Industrial talks | 03/03/2026 | By Darshana |  162

Dr Jitendra Singh Proposes India-Delaware Biomanufacturing Working Group

Dr Jitendra Singh proposed an India-Delaware Biomanufacturing Working Group to boost biotech collaboration, highlighting startup and R&D linkages. He also stressed supply chain resilience and regulatory cooperation during India-US talks to strengthen innovation, manufacturing and strategic life sciences ties.

Industrial talks | 03/03/2026 | By News Bureau |  138

ACC Extends Dr Rajeev Singh Raghuvanshi's appointment as Drugs Controller (India) for One Year

Dr Rajeev Singh Raghuvanshi receives a second one-year extension as head of CDSCO amid ongoing regulatory reforms and Schedule M implementation.

Industrial talks | 02/03/2026 | By News Bureau |  783

Argo Biopharma to Present Phase II Interim Data on BW-20805 for HAE at AAAAI 2026

Argo Biopharma’s investigational siRNA therapy BW-20805 showed sustained reduction in hereditary angioedema attack rates and plasma prekallikrein levels, with favorable safety, in Phase II interim data selected for AAAAI 2026.

Industrial talks | 27/02/2026 | By News Bureau |  233

Medicines and Healthcare products Regulatory Agency Approves Inluriyo for Advanced ER-Positive Breast Cancer

The UK regulator has approved Inluriyo (imlunestrant tosylate) for adults with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations after prior hormone therapy failure.

Industrial talks | 26/02/2026 | By News Bureau |  180

Boehringer Ingelheim Appoints Meenal Gauri as Managing Director for India and South Asia

Boehringer Ingelheim has named Meenal Gauri as Managing Director India, effective January 12, 2026, overseeing operations across five South Asian markets and joining the company’s India board.

Industrial talks | 25/02/2026 | By News Bureau |  222

Angelini Pharma, Quiver Bioscience Ink USD 120 Million Pact to Develop Genetic Epilepsy Therapies

Angelini Pharma and Quiver Bioscience have signed a multi-year collaboration to develop novel therapies for genetic epilepsies, combining AI-driven discovery tools with epilepsy expertise in a deal worth up to USD 120 million.

Industrial talks | 25/02/2026 | By News Bureau |  178

Boehringer Ingelheim India and NIPER Raebareli Sign MoU to Boost Pharma Education and Research

The MoU between NIPER Raebareli and Boehringer Ingelheim establishes a framework to strengthen academic and research collaboration in areas such as pharmaceutical technologies, novel drug delivery systems, joint research initiatives, academic exchange and capability-building programmes.

Industrial talks | 23/02/2026 | By News Bureau |  104

TuHURA Biosciences Files IND for TBS-2025 in Relapsed/Refractory mutNPM1 AML

TuHURA Biosciences has filed an IND with the FDA to evaluate its VISTA-targeting antibody TBS-2025 in combination with a menin inhibitor for relapsed/refractory mutNPM1 AML.

Industrial talks | 20/02/2026 | By News Bureau |  263

BioNTech files patent lawsuit against Moderna over COVID-19 vaccine technology

German biotechnology firm BioNTech has filed a patent infringement lawsuit against U.S.-based vaccine maker Moderna in a federal court in Delaware. The case centers on Moderna’s updated COVID-19 vaccine, mNEXSPIKE, which BioNTech claims uses technology protected under its patents.

Industrial talks | 20/02/2026 | By Darshana |  186